Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery technologies, entered a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Boehringer aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programs, with Boehringer Ingelheim...